[144] AXON ENTERPRISE, INC. SEC Filing

Rhea-AI Filing Summary

Axon Enterprise, Inc. reported a proposed sale under Rule 144 of 10,000 common shares by an insider through UBS Financial Services on 10/07/2025. The filing lists an aggregate market value of $7,137,353.00 for the shares and states the shares were acquired by option exercise on 11/15/2021 with cash payment. The filer also disclosed two recent sales by the same person: 10,000 shares on 08/11/2025 for $8,312,887.00 and 10,000 shares on 09/08/2025 for $7,436,415.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Full disclosure of acquisition details (date, method, payment) for the shares being sold
• Prior sales within three months are reported, improving transparency about insider dispositions

Negative

• No Rule 10b5‑1 plan date provided, so sales may not be pursuant to an affirmative written trading plan
• Repeated insider sales (three blocks of 10,000 shares reported) could increase short‑term supply pressure

Insights

Insider Transactions Analyst

Insider plans to sell 10,000 shares on 10/07/2025, continuing recent disposals.

The filing shows the securities were acquired by option exercise on 11/15/2021 and the sale is being arranged through UBS Financial Services. The aggregate market value reported is $7,137,353.00, which gives a per‑share implied value consistent with recent gross proceeds reported for prior sales.

Concentration risk is limited because the notice covers a single block of 10,000 shares; however, two prior sales of 10,000 shares each in 08/11/2025 and 09/08/2025 show an ongoing pattern of disposals by the same person. Monitor short-term trading flow around 10/07/2025 for potential liquidity impact.

Corporate Governance Specialist

Disclosure aligns with Rule 144 mechanics and includes standard seller certification.

The notice documents acquisition date, nature of acquisition (option exercise), payment method (cash), and prior sales within three months, which fulfills typical Rule 144 disclosure requirements. The seller signs the representation that no undisclosed material adverse information is known.

Because the filing does not state any trading plan date (Rule 10b5‑1) or additional contractual restrictions, investors should note only the explicit facts reported and not infer other arrangements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	10000	7137353.00	78504440	10/07/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/15/2021	Option Exercise	Issuer			10000	11/15/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick W. Smith 17800 N. 85TH ST. Scottsdale AZ 85255	Common	08/11/2025	10000	8312887.00
Patrick W. Smith 17800 N. 85th ST. Scottsdale AZ 85255	Common	09/08/2025	10000	7436415.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did AXON insider file on Form 144?

The filing notifies a proposed sale of 10,000 common shares to be sold through UBS Financial Services on 10/07/2025 with an aggregate market value of $7,137,353.00.

When and how were the shares being sold originally acquired?

The shares were acquired by option exercise on 11/15/2021 and payment was made in cash on that date.

Has the insider sold shares recently?

Yes. The filing lists prior sales by the same person of 10,000 shares on 08/11/2025 for $8,312,887.00 and 10,000 shares on 09/08/2025 for $7,436,415.00.

Does the filing state the sale is under a Rule 10b5‑1 plan?

No plan adoption date or instruction date for a Rule 10b5‑1 trading plan is provided in the notice.

Who is the broker named for the proposed sale?

The broker listed is UBS Financial Services, Inc., Eleven Madison Avenue, New York, NY.